Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
HIV-positive people with a higher viral load over a longer period appear more likely to develop hepatocellular carcinoma.
Indicators of liver health improved at the same rate among those with cirrhosis who were cured of hep C regardless of their HIV status.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
In an analysis of the liver health of a cohort of HIV/hep B–coinfected people, one third had significant fibrosis.
Scientists aren’t sure, but they know that the risk that a previous case of liver cancer will return remains high for those cured of hep C.
This is according to an analysis of multiple factors potentially related to a diabetes diagnosis in a large group of French people with HIV.
People who have a low CD4 count, have cirrhosis and take certain hep C drug regimens are less likely to be cured.
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
In a recent study of more than 600 HIV-positive adults, 93 percent were cured of hep C.
Those for whom Mavyret did not work the first time had a high cure rate with this intensified retreatment regimen.
AZT and ddI were the main drugs associated with liver damage in a new study.
These include a low CD4 count, having cirrhosis and taking certain hep C drug regimens.
Treatments to reduce inflammation could help make HIV even less of a threat to health than antiretrovirals can alone.
This finding applies to those with Child-Pugh A cirrhosis who are treated with the Viekira regimen or Technivie, with or without ribavirin.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.